TEVA-RANITIDINE SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

RANITIDINE (RANITIDINE HYDROCHLORIDE)

Pieejams no:

TEVA CANADA LIMITED

ATĶ kods:

A02BA02

SNN (starptautisko nepatentēto nosaukumu):

RANITIDINE

Deva:

75MG

Zāļu forma:

SOLUTION

Kompozīcija:

RANITIDINE (RANITIDINE HYDROCHLORIDE) 75MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

300ML

Receptes veids:

Prescription

Ārstniecības joma:

HISTAMINE H2-ANTAGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0115150005; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2020-06-10

Produkta apraksts

PRODUCT MONOGRAPH
PR
TEVA-RANITIDINE
(ranitidine tablets, Teva Standard)
150 mg and 300 mg Film Coated Tablets
PR
TEVA-RANITIDINE SOLUTION
(ranitidine oral solution, USP)
15 mg/mL
PR
TEVA-RANITIDINE INJECTION
(ranitidine injection, USP)
25 mg/mL
THERAPEUTIC CLASSIFICATION
HISTAMINE H
2
-RECEPTOR ANTAGONIST
Teva Canada Limited
Date of Revision:
30 Novopharm Court
May 19, 2015
Toronto, Ontario
M1B 2K9
Submission Control No: 179744
_Teva-Ranitidine _
_ _
_ _
_2 _
PRODUCT MONOGRAPH
PR
TEVA-RANITIDINE
(ranitidine tablets, Teva Standard)
150 mg and 300 mg Film Coated Tablets
PR
TEVA-RANITIDINE SOLUTION
(ranitidine oral solution, USP)
15 mg/mL
PR
TEVA-RANITIDINE INJECTION
(ranitidine injection, USP)
25 mg/mL
THERAPEUTIC CLASSIFICATION
HISTAMINE H
2
-RECEPTOR ANTAGONIST
ACTIONS AND CLINICAL PHARMACOLOGY
Ranitidine is an antagonist of histamine at gastric H
2
-receptor sites. Thus, ranitidine
inhibits both basal gastric secretion and gastric acid secretion
induced by histamine,
pentagastrin and other secretagogues. On a weight basis ranitidine is
between 4 and 9
times more potent than cimetidine. Inhibition of gastric acid
secretion has been observed
following intravenous, intraduodenal and oral administration of
ranitidine. This response
is dose-related, a maximum response being achieved at an oral dose of
300 mg/day.
Pepsin secretion is also inhibited but secretion of gastric mucus is
not affected. Ranitidine
does not alter the secretion of bicarbonate or enzymes from the
pancreas in response to
secretin and pancreozymin.
Ranitidine is rapidly absorbed after oral administration of 150 mg
ranitidine, peak plasma
concentrations (300 to 550 ng/mL)
occurred after
1 to 3 hours. Two distinct peaks or a
plateau in the absorption phase result from reabsorption of drug
excreted into the
intestine. These plasma concentrations are not significantly
influenced by the presence of
food in the stomach at the time of the oral administration nor by
regular doses of
antacids.
Bioavailability of oral ranitidine is approximately 50% to 60%